Literature DB >> 10811073

Scleral rupture during retinal detachment surgery: risk factors, management options, and outcomes.

H Tabandeh1, C Flaxel, P M Sullivan, P K Leaver, H W Flynn, J Schiffman.   

Abstract

OBJECTIVE: To evaluate the potential risk factors, management strategies, and outcomes of scleral rupture during retinal detachment (RD) surgery.
DESIGN: Case-control study. PARTICIPANTS AND CONTROLS: Fourteen consecutive patients with scleral rupture during RD surgery (cases) and 65 consecutive patients who underwent RD surgery without scleral rupture (controls). INTERVENTION: Demographic and clinical data were abstracted from patients' medical records. OUTCOME MEASURES: Visual acuity and retinal attachment status at the last examination.
RESULTS: Significant risk factors for scleral rupture during RD surgery were reoperation after failed RD surgery (71 % vs. 32%), and pre-existing scleral pathologic condition (29% vs. none). The site of rupture was in the bed of a previously placed scleral buckle in all patients with a previous buckling surgery. Repair of the rupture included scleral sutures in eight (57%), scleral patch graft in four (29%), and placement of a scleral buckle over the site in two (14%) eyes. Eleven (79%) underwent vitrectomy with retinal tamponade by gas (n = 4) or silicone oil (n = 7). Complications observed postoperatively included vitreoretinal incarceration (n = 3), vitreous hemorrhage (n = 2), suprachoroidal hemorrhage (n = 2) and subretinal hemorrhage (n = 3). In the 14 eyes with scleral rupture, the final visual acuity was > or =20/40 in 1 (7%), 20/50 to 20/200 in 5 (36%), and <20/200 in 8 (57%). Ten (71 %) had proliferative vitreoretinopathy develop. The retina was attached in 7 (50%), 6 (43%) had localized peripheral detachment, and 1 had a total retinal detachment. The vision improved in 4 (29%), was unchanged in 5 (36%), and was worse than before surgery in 5 (36%). In the 65 controls, the visual acuity at the time of the last examination was > or =20/40 in 26 (40%), 20/50 to 20/200 in 21 (32%), and <20/200 in 18 (28%). Sixty three (97%) patients had complete retinal reattachment, 1 (2%) had a localized peripheral RD, and 1 (2%) had an RD involving the posterior pole. After surgery, the vision improved in 45 (69%), was unchanged in 15 (23%), and was worse in 5 (8%) of the control eyes. The visual and anatomic outcomes of the eyes with scleral rupture were significantly worse than in the control group (P = 0.002 and P < 0.001, respectively).
CONCLUSIONS: Risk factors associated with intraoperative scleral rupture include reoperation for failed RD surgery and pre-existing scleral pathology. Although this complication may be compatible with a good visual outcome in some patients, a high incidence of persistent or recurrent RD with proliferative vitreoretinopathy worsens the visual outcome for most patients with this complication.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811073     DOI: 10.1016/s0161-6420(00)00033-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Preserved scleral patch graft for unexpected extreme scleral thinning found at the scleral buckling procedure: a case report.

Authors:  Spela Stunf; Xhevat Lumi; Brigita Drnovšek-Olup
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

2.  Scleral rupture during intraoperative silicone oil injection in pars plana vitrectomy.

Authors:  Ana Laura Domínguez Yates; Jimena Rojas; Mario Joaquín Saravia
Journal:  Am J Ophthalmol Case Rep       Date:  2019-06-29

3.  RD repair using 360-degree scleral graft for extensive scleral ectasia in a patient with Ehlers Danlos syndrome.

Authors:  Shane Whitlow; Zubair Idrees
Journal:  Am J Ophthalmol Case Rep       Date:  2019-09-13

Review 4.  Scleral Buckling: A Review of Clinical Aspects and Current Concepts.

Authors:  Matteo Fallico; Pietro Alosi; Michele Reibaldi; Antonio Longo; Vincenza Bonfiglio; Teresio Avitabile; Andrea Russo
Journal:  J Clin Med       Date:  2022-01-09       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.